Single-agent checkpoint blockade changed oncology. Combination immunotherapy is where the field believes the next major improvements will come — and the logic is sound but complicated. Releasing the immune brake with PD-1 or CTLA-4 inhibitors is necessary but not sufficient for most tumor types. The T cells also need a target, a co-stimulatory signal, and a tumor microenvironment that doesn't immediately exhaust them. The 2026 trial landscape reflects all of those requirements simultaneously: hundreds of combination studies testing checkpoint inhibitors against ADCs, bispecific antibodies, cancer vaccines, and other immune modulators across virtually every tumor type. Making sense of what has real signal versus what's exploratory fishing requires understanding why the combinations are being tested — not just which drugs are in the trial.
This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
Checkpoint immunotherapy has transformed oncology, but most patients across most tumor types still don't derive durable benefit from single-agent PD-1/PD-L1 inhibition. In 2026, the trial landscape is dominated by combination strategies addressing the mechanisms of resistance: dual checkpoint blockade, novel co-inhibitory targets (LAG-3, TIGIT, TIM-3), bispecific antibodies that redirect T cells while co-stimulating them, and mRNA neoantigen vaccines. Key data: mRNA-4157/V940 plus pembrolizumab reduced melanoma recurrence by 44% vs. pembrolizumab alone in Phase 2b. Tarlatamab (DLL3xCD3 bispecific) achieved 40% ORR in heavily pretreated SCLC and received accelerated FDA approval in 2024. SKYSCRAPER-01 (tiragolumab anti-TIGIT) failed in Phase 3 — illustrating that Phase 2 signals don't always translate, even in mechanistically rational combinations.
Why Single-Agent Checkpoint Blockade Has Limits
PD-1/PD-L1 inhibitors achieve durable responses in 20–40% of patients in PD-L1-high tumors — substantially less in unselected populations. The mechanisms of primary resistance are well-characterized now. "Cold" tumors have no pre-existing tumor-infiltrating lymphocytes to unleash. HLA downregulation or beta-2 microglobulin loss prevents tumor antigen presentation. Alternative co-inhibitory checkpoints (LAG-3, TIM-3, TIGIT, VISTA) upregulate to compensate for PD-1 blockade. Immunosuppressive cells in the tumor microenvironment — regulatory T cells, M2-polarized macrophages, myeloid-derived suppressor cells — actively extinguish T cell activity even when the brake has been released. WNT/beta-catenin signaling in certain tumors physically excludes T cells from the tumor core.
Each of these resistance mechanisms is a potential combination target. The difficulty is that adding a second immunotherapy agent usually amplifies immune-related adverse events (irAEs) — colitis, hepatitis, pneumonitis, endocrinopathies — which can be life-threatening at high rates. The field has learned that synergistic anti-tumor activity doesn't require additive toxicity if mechanisms are chosen wisely and doses optimized. That's what most current combination trials are working out.
Dual Checkpoint Blockade: Optimizing What Works
Nivolumab plus ipilimumab established proof of concept in melanoma, achieving 5-year overall survival rates of approximately 52% — more than double what was seen with chemotherapy in the pre-immunotherapy era. CHECKMATE-227 extended the combination to NSCLC (OS HR 0.79 vs. platinum chemotherapy in PD-L1-high disease). CHECKMATE-9LA added two cycles of chemotherapy to nivolumab/ipilimumab to bridge the immunotherapy activation lag, improving early landmark survival rates.
The 2026 optimization question: can lower-dose ipilimumab (1 mg/kg instead of 3 mg/kg) maintain the anti-tumor efficacy while substantially reducing the grade 3–4 irAEs that make the 3 mg/kg combination difficult to manage? The TITAN-1 trial directly compares 1 mg/kg versus 3 mg/kg ipilimumab with nivolumab in NSCLC, powered to demonstrate non-inferiority on OS with superiority on treatment-related adverse events. The LAG-3 angle: relatlimab plus nivolumab (Opdualag) was approved for melanoma in 2022 based on RELATIVITY-047 Phase 3 data showing improved PFS versus nivolumab alone (10.1 vs. 4.6 months). RELATIVITY-048 is now testing relatlimab/nivolumab versus nivolumab/ipilimumab in melanoma, with the hypothesis that LAG-3 blockade provides similar synergy to CTLA-4 inhibition but with more manageable toxicity.
TIGIT, TIM-3, and the Phase 3 Failure Lesson
TIGIT (T cell immunoreceptor with Ig and ITIM domains) and TIM-3 (T cell immunoglobulin and mucin domain-3) are expressed on exhausted T cells and have been among the most pursued checkpoint targets after LAG-3. The CITYSCAPE Phase 2 trial of tiragolumab (anti-TIGIT, Genentech) plus atezolizumab showed encouraging NSCLC signals. The Phase 3 SKYSCRAPER-01 trial — 534 patients, PD-L1-high NSCLC, tiragolumab plus atezolizumab versus atezolizumab alone — failed to meet its primary endpoints of PFS or OS improvement. This was a significant setback that illustrates a consistent pattern in oncology: positive Phase 2 signals can be generated by chance, patient selection bias, or endpoint choice, and don't reliably predict Phase 3 success.
Despite SKYSCRAPER-01, TIGIT remains an active target — with the hypothesis that Fc-mediated depletion of TIGIT+ regulatory T cells in the tumor microenvironment was the missing mechanism in tiragolumab's Fc-competent design. Domvanalimab (ARC-7, Arcus) is an Fc-silent anti-TIGIT designed to prevent NK cell-mediated killing of TIGIT+ TILs, combined with zimberelimab (PD-1 inhibitor) in the STAR-221 Phase 3 for first-line NSCLC. Vibostolimab (anti-TIGIT, Merck) plus pembrolizumab is in Phase 3 for NSCLC and cervical cancer. For TIM-3, cobolimab (GSK) plus dostarlimab is in Phase 2/3 for AML and NSCLC with early activity signals.
Bispecific Antibodies: T Cell Redirection Plus Checkpoint
Bispecific antibodies can simultaneously target two pathways — redirecting T cells to tumors while removing inhibitory signals, or blocking two checkpoints with one molecule. Cadonilimab (AK104, Akeso) simultaneously blocks PD-1 and CTLA-4 with a single molecule designed to preferentially accumulate where both ligands are co-expressed in the tumor microenvironment, potentially offering dual blockade with reduced systemic CTLA-4 toxicity. Phase 2 data in recurrent/metastatic cervical cancer showed 33% ORR in PD-L1-positive disease; Phase 3 in cervical cancer and gastric cancer is enrolling.
Tarlatamab (DLL3xCD3, Amgen) redirects T cells to DLL3-expressing small cell lung cancer cells via a bispecific T cell engager (BiTE) mechanism. The DeLLphi-301 Phase 2 demonstrated a 40% ORR in patients who had received two or more prior therapies — a remarkable result in SCLC, a tumor type with historically dismal second-line outcomes. FDA granted accelerated approval in May 2024. Phase 3 DeLLphi-304 is now comparing tarlatamab to topotecan or irinotecan as second-line SCLC therapy — the definitive test of whether this translates to survival improvement. HER2-targeted and EGFR-targeted bispecifics combining tumor targeting with T cell engagement or checkpoint relief are in Phase 1/2 for breast, gastric, and lung cancers.
mRNA Neoantigen Vaccines: The 44% Reduction That Changed the Field
The convergence of mRNA vaccine technology with cancer immunotherapy is one of the most actively pursued areas in 2026 oncology. Personalized mRNA neoantigen vaccines — constructed from sequencing each patient's tumor and identifying mutations unique to that tumor — prime T cells against tumor-specific antigens that normal cells don't carry. The KEYNOTE-942 Phase 2b trial (mRNA-4157/V940, Moderna/Merck, combined with pembrolizumab vs. pembrolizumab alone) in resected high-risk melanoma showed a 44% reduction in the risk of recurrence or death compared to pembrolizumab alone. The combination was meaningfully better than checkpoint inhibitor alone, suggesting the vaccine was successfully priming new anti-tumor immune responses rather than just adding redundant checkpoint blockade.
Phase 3 KEYNOTE-942-003 is now enrolling in high-risk resected melanoma, and parallel Phase 2 trials are evaluating mRNA-4157 in adjuvant NSCLC, bladder cancer, and head and neck cancer. The manufacturing challenge is real — each vaccine takes several weeks to make from tumor biopsy to product — but the platform is commercially viable at scale, as demonstrated by COVID-19 mRNA manufacturing. BNT111 (BioNTech), targeting four shared melanoma antigens (NY-ESO-1, MAGE-A3, tyrosinase, TPTE), is in Phase 2 combined with cemiplimab for unresectable melanoma that progressed on prior PD-1 therapy.
CAR-T Combinations: Solving the Solid Tumor Problem
CAR-T cell therapy has achieved spectacular results in hematologic malignancies — 50–80% complete remission rates in relapsed/refractory B cell lymphomas and ALL with approved products (tisagenlecleucel, axicabtagene ciloleucel, lisocabtagene maraleucel). Solid tumors are a fundamentally different environment: immunosuppressive tumor microenvironments inhibit CAR-T persistence, heterogeneous antigen expression allows antigen-loss escape, physical barriers to tumor penetration limit access, and T cell exhaustion develops rapidly in the chronic inflammatory context of a solid tumor.
The combination strategy addresses CAR-T dysfunction at multiple levels. CART-meso plus pembrolizumab in mesothelioma and lung cancer tests whether checkpoint inhibition prevents the exhaustion of mesothelin-directed CAR-T cells arriving in an immunosuppressive environment. Armored CAR-T cells engineered to secrete IL-12, IL-18, or IL-21 constitutively aim to reshape the tumor microenvironment from within rather than depending on systemic cytokine supplementation. GD2-directed CAR-T combined with anti-GD2 antibody dinutuximab is in Phase 2 for neuroblastoma. The CAR-T plus oncolytic virus approach — using engineered viruses to lyse tumor cells and create an inflammatory, immunostimulatory environment that supports CAR-T function — is in Phase 1 for glioblastoma and colorectal cancer. We don't know yet which of these will translate, but the mechanistic logic of addressing CAR-T dysfunction specifically, rather than hoping the cells persist in a hostile environment, is more rational than earlier solid tumor CAR-T attempts.
Key Trial Data Points
- mRNA-4157/V940 plus pembrolizumab: 44% reduction in melanoma recurrence or death vs. pembrolizumab alone in KEYNOTE-942 Phase 2b — Phase 3 enrolling 2026 across melanoma and other tumor types.
- Tarlatamab (DLL3xCD3): 40% ORR in 2+ prior therapy SCLC; FDA accelerated approval May 2024; Phase 3 (DeLLphi-304) vs. standard second-line chemotherapy now enrolling.
- SKYSCRAPER-01 failure for tiragolumab (anti-TIGIT) in Phase 3 NSCLC illustrates Phase 2 signal unreliability; next-generation Fc-silent anti-TIGIT (domvanalimab) in Phase 3 STAR-221.
- Relatlimab/nivolumab (Opdualag): approved 2022 for melanoma (PFS 10.1 vs. 4.6 months vs. nivolumab alone); RELATIVITY-048 now testing vs. nivolumab/ipilimumab.
- Cadonilimab (dual PD-1/CTLA-4 bispecific): 33% ORR in PD-L1+ recurrent/metastatic cervical cancer Phase 2; Phase 3 enrolling in cervical and gastric cancer.